This trial is testing a new drug in combination with the standard drug therapy for high risk diffuse large B-cell lymphoma to see if it is more effective than the standard therapy alone.
2 Primary · 7 Secondary · Reporting Duration: From registration to death due to any cause, assessed up to 5 years
Experimental Treatment
44 Total Participants · 1 Treatment Group
Primary Treatment: Parsaclisib · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: